Triage Performance and Physiological Predictors of Serious Illness in Febrile Children in the Pediatric Emergency Department
NCT07739004
Body Temperature Changes, Disease Attributes
Kayseri, Talas, Turkey (Türkiye)
View Trial DetailsNCT Number: NCT07332793
The goal of this observational study is to learn how changes in immune cells are linked to outcomes in adults with severe infection who are treated in the intensive care unit (ICU). Severe infections, including sepsis, can affect how the immune system works and may lead to poor recovery or death. Researchers want to better understand these immune changes so that people at higher risk can be identified earlier.
The main questions this study aims to answer are:
Are certain immune cell patterns linked to survival or death within 28 days? Are these immune patterns linked to organ failure or longer stays in the ICU? Participants will be adults with severe infection who are admitted to the ICU as part of their routine medical care. This study does not change or add to their medical treatment.
Participants will:
Have small blood samples collected at several time points during their ICU stay Allow researchers to review their medical records, including test results and outcomes Researchers will analyze immune cells in the blood and relate these findings to clinical outcomes. The results may help improve future risk assessment and understanding of immune changes in people with severe infection.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
This study is a prospective observational cohort study conducted in adult patients with severe infection who are admitted to the intensive care unit (ICU). The study aims to characterize dynamic changes in immune cell profiles during critical illness and to examine how these changes are associated with short-term clinical outcomes.
Severe infection, including sepsis, is frequently accompanied by profound alterations in immune function. While some individuals recover, others develop persistent organ dysfunction or die despite standard medical care. Current clinical and laboratory markers provide limited information about immune status and do not reliably predict outcomes. A more detailed understanding of immune cell patterns in critically ill patients may help improve risk stratification and future clinical decision-making.
Adult patients (aged 18 years or older) who are diagnosed with severe infection according to established clinical criteria and admitted to the ICU will be screened for eligibility. Participants will be enrolled consecutively after informed consent is obtained from the patient or a legally authorized representative. This study does not involve any experimental intervention, and all participants will receive standard medical care as determined by their treating clinicians.
Peripheral blood samples will be collected at predefined time points during the ICU stay, including early and later phases of illness. These samples will be used to assess immune cell populations and their activation states using established laboratory methods. In addition, routinely collected clinical data will be recorded, including demographic information, severity of illness scores, laboratory test results, organ support measures, and clinical outcomes.
The primary clinical outcome of interest is all-cause mortality within 28 days after ICU admission. Secondary outcomes include the development of organ dysfunction and length of ICU stay. Immune cell data will be analyzed in relation to these outcomes to identify immune patterns that are associated with different clinical trajectories.
Statistical analyses will focus on describing immune cell distributions, identifying immune phenotypes using data-driven approaches, and evaluating associations between immune patterns and clinical outcomes while accounting for relevant clinical variables. The results of this study are intended to improve understanding of immune alterations in severe infection and to inform future research aimed at improving prognosis assessment and patient management.
All data will be collected and stored in accordance with ethical and regulatory requirements. Participant confidentiality will be maintained through coded identifiers, and access to identifiable information will be restricted to authorized study personnel.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Within 28 days after ICU admission
All-cause mortality assessed within 28 days after admission to the intensive care unit.
Time frame: Length of stay in the intensive care unit, measured in days from ICU admission to ICU discharge.
From ICU admission to ICU discharge
Time frame: Organ dysfunction assessed using routinely collected clinical data during the first 28 days after ICU admission.
Within 28 days after ICU admission
Time frame: Within 28 days after ICU admission
Secondary infection during ICU stay
Time frame: At baseline (ICU admission), Day 7, and Day 14
The expression levels of selected G protein-coupled receptors (GPCRs) on peripheral blood regulatory T cells (Tregs), quantified by flow cytometry and expressed as mean fluorescence intensity (MFI) and/or percentage of positive cells.
Time frame: At ICU admission and during ICU stay
Molecular phenotypes of peripheral immune cell subsets, will be assessed by multiparameter flow cytometry.
Contact information is provided by the study sponsor or research team.
Second Affiliated Hospital of Wenzhou Medical University
Other
Acronym: PIC-PSI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07739004
Body Temperature Changes, Disease Attributes
Kayseri, Talas, Turkey (Türkiye)
View Trial DetailsNCT07739251
Infections, Inflammation
View Trial DetailsNCT07670624
Biomarker Discovery, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Wroclaw, Poland
View Trial DetailsNCT07735741
Infections, Inflammation
Falls Church, Virginia, United States
View Trial Details